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Abstract 
Background: Ailanthone (Aila) is a natural active compound isolated from the Ailanthus altissima, 
-inhibitory effect against several cancer cell 
lines. Advanced bladder cancer is a common disease characterized by a frequent onset of resistance 
to cisplatin-based therapy. The cisplatin (CDDP) resistance is accompanied by an increase in Nrf2 
protein expression which contributes to conferring resistance. Recently, we demonstrated a cross-
talk between Nrf2 and YAP. YAP has also been demonstrated to play an important role in 
chemoresistance of bladder cancer. 
 Purpose: We analyzed the antitumor effect of Aila in sensitive and CDDP-resistant bladder cancer 
cells and the molecular mechanisms involved in Aila activity. 
Study design: Sensitive and CDDP-resistant 253J B-V and 253J bladder cancer cells, and 
intrinsically CDDP-resistant T24 bladder cancer cells were used. Cells were treated with  diverse 
concentrations of Aila and proliferation, cell cycle, apoptosis and gene expressions were 
determined. 
Methods: Aila toxicity and proliferation were  determined by MTT and colony forming methods, 
respectively. Cell cycle was determined at cytofluorimeter by PI staining method Apoptosis was 
detected using Annexin V and PI double staining followed by quantitative flow cytometry. 
Expressions of  Nrf2, Yap, c-Myc, and house-keeping genes were determined by western blot with 
specific antibodies. Cell migration was detected by wound healing and Boyden chamber analysis. 
Results: Aila inhibited growth of sensitive and CDDP-resistant  bladder cancer cells with the same 
effectiveness, and reduced cell migration with higher effectiveness in CDDP resistant cells. 
Interestingly, Aila strongly reduced Nrf2 expression in all cell lines. Cell cycle analysis revealed an 
accumulation of Aila-treated cells in G0/G1 phase.  Moreover, Aila significantly reduced YAP and 
c-Myc protein expression. The random and the oriented migration were strongly inhibited by Aila 
treatment, in particular in CDDP-resistant cells. 
Conclusions: Aila, inhibited proliferation and invasiveness of bladder cancer cells. Its high 
effectiveness in CDDP resistant cells could be related to the inhibition of Nrf2 , YAP and c-Myc 
expressions. Aila could represent a new tool to overcome CDDP resistance in bladder cancer. 
 
Keywords: Ailanthone; bladder cancer;  CDDP-resistance; Nrf2; Yap; c-Myc. 
 
Abbreviation: Aila, Ailanthone; CDDP, Cisplatin; Nrf2, NF-E2-related factor 2; YAP, yes-
associated protein; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Keap1, 
Kelch-like ECH-associated protein 1; ARE, antioxidant response element; EpRE, electrophile 
response element; RPMI 1640, Roswell Park Memorial Institute medium; FBS, fetal bovine serum; 
EDTA: Ethylenediaminetetraacetic acid; SDS, sodium dodecyl sulfate; TBS: tris-buffered saline; 
GAPDH, glyceraldehyde 3 phosphate dehydrogenase; GSTA4, Glutathione S-transferase A4; PI, 
propidium iodide, FITC, fluorescein isothiocyanate;  
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Introduction 
Ailanthone (Aila) -11,20-Epoxy-1,11,12-trihydroxypicrasa-3,13(21)-diene-2,16-
dione] is a natural active compound isolated from the plant Ailanthus altissima (Bray et al., 1987). 
Aila has a wide spectrum of biological activities, it is traditionally used to treat ascariasis, diarrhoea, 
spermatorrhoea, bleeding and gastrointestinal diseases, and it has been found to have anti-
inflammatory activity  (Kim et al., 2015). Aila -
inhibitory effect against several cancer cell lines (Wang R. et al., 2016), but the mechanisms 
involved in the antiproliferative activity of Aila are not completely elucidated and they seem to be 
related to the cancer cell type. Indeed, in some cell models Aila induced G0/G1-phase cell cycle 
arrest, and triggered DNA damage and apoptosis pathway (Zhuo et al., 2015), in others, Aila 
induced G2/M phase cell cycle arrest and an apoptosis through downregulation of Bcl2 and 
upregulation of Bax (Chen Y et al., 2017). Ni et al. (2017) found that Aila inhibited the growth of 
several lung cancer cells through repression of DNA replication via RPA1 down regulation. He et 
al. (2016) demonstrated that Aila was a potent inhibitor of androgen receptor and it was able to 
overcome resistance in castration-resistant cancer cells through the binding with the co-chaperone 
p23 protein.  
Urothelial carcinoma of the bladder is a common malignancy in men. At the initial diagnosis,  about 
s muscle-invasive 
bladder cancers. Muscle-invasive bladder cancer is associated with poor prognosis. Standard of care 
for muscle-invasive bladder cancer is cystectomy combined with platinum-based chemotherapy 
regimens (Madersbacher et al., 2003). The clini -based chemotherapy is 
limited and the majority of the patients eventually develop cisplatin-resistant disease (Shah et al., 
2011). Thus, the identification  of novel agents able to overcome this resistant disease is an urgent 
and unmet need.   
In bladder cancer cells, we previously demonstrated that the CDDP resistance was accompanied by 
an increase in Nrf2 (NF-E2-related factor 2) protein expressions which contributes to conferring 
CDDP resistance (Ciamporcero et al., 2018). The transcription factor Nrf2 is the master regulator of 
antioxidant and cytoprotective genes  (Rojo de la Vega et al., 2018). It is present in the cytoplasm 
bound to Keap1 (Kelch-like ECH-associated protein 1) which,  by forming a complex with Cul3 
and Rbx1, and this E3 ubiquitin ligase complex, is able to ubiquitinate Nrf2, resulting in Nrf2 
proteasomal degradation. In response to an increase of oxidative stress, the cysteine residues of 
Keap1 become oxidized, resulting in a conformational change of the Keap1 Nrf2 complex which 
prevents Nrf2 ubiquitination  (Itoh  et al., 2004). As a consequence,  Nrf2 accumulates in nuclei, 
and after heterodimerization with Maf proteins, binds antioxidant response element 
(ARE)/electrophile response element (EpRE) and activates target genes for cytoprotection (Itoh  et 
al., 2004).  Due to its cytoprotective role, the Nrf2 increase in resistant cells has been proposed as 
an important tool for maintaining drug resistance (No et al, 2014). Indeed,  Nrf2 overexpression is 
associated with clinically relevant CDDP resistance in bladder cancer patients (Hayden et al., 2014).  
Recently,  in bladder cancer cells, we demonstrated a cross-talk between Nrf2 and Yap:  Nrf2 
silencing and glutathione depletion reduced YAP expression, possibly through the inhibition of  
GABP transcriptional activity  (Ciamporcero et al., 2018). Moreover, YAP protein is also involved 
in maintaining antioxidant capacity: the stimulation of YAP prevents, whereas the down-regulation 
of YAP promotes oxidative stress-induced cell death in cardiomyocytes (Tao et al., 2016). 
Increasing evidence has demonstrated the involvement of YAP in chemoresistance of several types 
of cancers. YAP, is a key component of the Hippo tumor-suppressor pathway (Harvey et al., 2013). 
Hippo pathway-mediated YAP phosphorylation on Ser127 leads to its cytoplasm sequestration or 
ubiquitination and degradation  (Zhao et al., 2010). Conversely, unphosphorylated YAP translocates 
into the nucleus where it binds to the TEAD transcription factor, triggering the expression of several 
downstream transcriptional targets involved in organ size control, cell proliferation, migration and 
survival, such as c-Myc, cyr 61 and survivin. Indeed, YAP expression inhibition results in reduced 
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cell proliferation and increased cell death (Zhao et al., 2008). YAP expression and nuclear 
localization strongly correlate with poor patient outcome and the progression of several tumors, 
including bladder cancer  (Liu et al., 2013). The constitutive expression and activation of YAP was 
inversely correlated with in vitro and in vivo CDDP sensitivity of urothelial cell carcinoma cells: 
YAP overexpression protects, while YAP knockdown sensitizes cancer cells to chemotherapy and 
radiation effects via increased accumulation of DNA damage and apoptosis (Ciamporcero et al., 
2016). Moreover, the knockdown of YAP and the silencing of Nrf2 enhanced sensitivity of bladder 
cancer cells to CDDP and reduced their migration (Ciamporcero et al., 2018).  
Aila has been demonstrated to exhibit in vitro growth-inhibitory effects against several cancer cell 
lines. However, the antitumor activity in bladder cancer cells, sensitive and resistant to CDDP 
treatment, remains to be elucidated.  In this paper we demonstrated, for the first time, that Aila is 
able to inhibit proliferation and migration in these cell models, in particular in CDDP resistant cells,  
and that these effects could be linked to its ability to inhibit Nrf2, Yap and Myc expressions. 
 
Materials and Methods  
 
Cells and  culture conditions  
253J B-V and 253J cell lines were kindly provided by Dr Colin Dinney (MD Anderson Cancer 
Center). Human cell line T24 was purchased from ATCC (Manassas, VA, USA). These cells were 
esistance  in 253J B-V and 253J was 
induced and maintained as previously described (Ciamporcero et al., 2018).  
 
MTT assay 
The toxic effect of Aila was determined through the 3-(4,5-dimethyl thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as previously described (Ciamporcero et al., 2018). This 
colorimetric assay may be interpreted as a measure of both cell viability and cell proliferation 
(Sylvester, 2011). Cells were seeded (800 -supplemented 
medium and treated with different concentrations of Aila (Baoji Herbest Bio-Tech Co., Ltd. Baoji 
city Shannxi Provence China). To confirm the CDDP resistance, CDDP was added at the 
Untreated cells were used as control. After 72 hours, 
the drug was removed and MTT assay was performed.  
 
Colony-forming assay 
 PBS, and seeded (500 cells/well) into a six-well plate and left 
overnight to attach. After 24 h, the cells were treated with the compounds and the medium was 
changed after 72 h. Cells were cultured for 9
solution of 90% crystal violet (Sigma Aldrich), 10% methanol.  
 
Lysate preparation and western blot analysis 
Lysate preparation and western blot analysis were performed as previously described (Ciampocero 
et al,, 2018). Antibodies used were as follows: glyceraldehyde 3 phosphate dehydrogenase 
-actin (sc-47778), YAP (sc15407), Nrf2 
(sc 722),  -tubulin (04-1117, Millipore, Billerica, MA, USA); c-Myc (clone 9E10, sc 40, Santa 
Cruz Biotechnology, CA), GSTA4  (Glutathione S-transferase A4)  (SAB1401164, Sigma
Aldrich). The detection of the bands was carried out after reaction with chemiluminescence reagents 
-201697) 
autoradiography. 
 
Cytofluorimetric analysis 
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Adherent and non-adherent treated and control cells were harvested 24 hours after the treatment 
resuspended in a buffer containing 0.02 mg/ml RNase A (Worthington), 0.05 mg/ml propidium 
iodide (PI) (Sigma Aldrich), 0.2% v/v Nonidet P-40 (Sigma Aldrich), 0.1% w/v sodium citrate 
(Sigma Aldrich), and analyzed with a FACScan cytometer (Becton Dickinson, Accuri). For 
apoptosis analysis 1x106 cells were harvested and stained with FITC-Annexin 5 and PI according to 
the manufacter protocol (FITC Annexin V Apoptosis Detection Kit 
556547). 
 
Cell motility assay 
In the wound-healing assay, after starvation for 18 um-free medium, cells were plated 
onto six-well plates (106 cell/well) and grown to confluence. Cell monolayers were wounded by 
scratching with a pipette tip along the diameter of the well, and they were washed twice with serum-
free medium before their incubation with diverse concentrations 
In order to monitor cell movement into the wounded area, five fields of each wound were 
photographed immediately after the scratch (T0 ours (Dianzani et al., 2014). The 
endpoint of the assay was measured by calculating the reduction in the width of the wound after 24 
hours and compared to T0 which is set at 100%.  The area of wound healing was calculated by 
using the ImageJ software (Schneider et al., 2012). In the Boyden chamber (BD Biosciences, San 
Jose, CA) invasion assay, cells (2  mL 1 Matrigel-
Italy) in serum-free medium with or without increasing concentration of the Aila (0.01, 0.05 and 0.1 
the basolateral chamber as a chemo attractant. 
ours, cells on the apical side were wiped off with Q-tips. Cells on the bottom of the filter 
were stained with crystal violet and counted (five fields of each triplicate filter) with an inverted 
microscope.  
 
Statistical analysis 
one-way ANOVA followed by the Bonferroni multiple comparison post-test using GraphPad InStat 
software (San Diego, CA, USA). Values  
Results 
 
Aila effect on bladder cancer cell growth and colony forming. 
To analyze the ability of Alia to affect cell growth and  colony forming of sensitive and CDDP-
resistant bladder cancer cells,  253J B-V and 253J B-V resistant to CDDP (253J B-V C-r), 253J and 
253J resistant to CDDP  (253J C-r), and T24 (intrinsically CDDP resistant) cells were exposed to 
different doses of Aila. Results obtained demonstrated that the Alia was  more effective than CDDP 
in reducing cell growth of 253J B-V  cells and, in particular, Aila reduced the growth of 253J B-V 
C-r cells to the same extent as the sensitive cells (Fig. 1A). Colony forming assay confirmed the 
effectiveness of Aila treatment in sensitive and CDDP resistant 253J B-V cells (Fig. 1B). 
The cytotoxic and antiproliferative effect of Aila was demonstrated in 253J cells, also (Fig. 2). The 
in sensitive and CDDP resistant cells (Fig. 2A). The colony forming assay also confirmed the 
effectiveness of Aila in 253J C-r cells (Fig. 2B). The third cell line employed in our experiments 
was the T24 cells. This cell line has been demonstrated to be resistant not only to CDDP but also to 
other DNA damaging agents such as the anthracycline antibiotic doxorubicin and the Podophyllum 
peltatum toxin etoposide (Ciamporcero et al.,  2016). Analogously,  to that observed in the previous 
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cell lines,  Aila reduced T24 cell growth and colony forming to a higher extent than CDDP (Fig.3 
A, B).  
 
Aila effects on Nrf2 and Nrf2 target gene expressions 
We previously demonstrated that Nrf2 expression is higher in CDDP-resistant bladder cancer cells 
than in sensitive cells and that the silencing of Nrf2 in CDDP resistant bladder cancer cells, can 
sensitize them to CDDP and reduce cell viability (Ciamporcero et al., 2018). Since the Aila 
treatment reduced proliferation and colony forming of CDDP resistant cells to the same extent as 
the sensitive cells, we analyzed whether Aila could reduce Nrf2 expression in these cell lines. The 
analysis were performed after 24 and 48 hours from the treatment. Results demonstrated that Nrf2 
expression was inhibited until 48 hours in a dose dependent way in both sensitive and resistant 
bladder cancer cells (Fig. 4 A,B). The reduction of Nrf2 protein was confirmed by the contemporary 
reduction of GSTA4, a Nrf2 target gene (Fig 5 A,B). 
 
Effect of Aila on cell cycle and apoptosis of bladder cancer cells 
To deepen the antiproliferative activity by Aila we performed the analysis of cell cycle and 
apoptosis in sensitive and CDDP-resistant 253J B-V cells.  In both cell lines, Aila (from 0.1 to 1 
) induced a significant increase in G0/G1 cells (Fig. 6 A,B), whereas treatments with the same 
concentrations of Aila did not induce increase of apoptotic cells (data not shown).  
 
Aila inhibits YAP and c-Myc protein expression 
On the basis of our previous results that indicated a cross-talk between Nrf2 and YAP expression, 
we analyzed in 253J B-V and 253J B-V C-r the expression of YAP. Moreover, since Myc and 
YAP-TEAD integrate mitogenic and mechanical cues at the transcriptional level to control cell 
proliferation  (Croci  et al.,  2017), c-Myc protein expression was also examined. Results obtained 
demonstrated that Aila inhibited YAP and c-Myc expression, both in sensitive and, particularly, in 
resistant cell lines, which express YAP at high levels (Fig.7 A,B). The inhibition was dose-
dependent and persisted until 48 hours from the treatment. 
 
Effects of Aila on migration of bladder cancer cells 
YAP and Nrf2 also control the migration of cancer cells (Rojo de la Vega et al., 2018) which 
contributes to their  metastatic properties. Since Aila inhibited the expression of both Nrf2 and YAP 
proteins, we analyzed its effect on cell migration. Cell motility was initially assessed using a wound 
healing assay evaluating random cell migration in the presence or absence of diverse concentrations 
of Aila . Analysis of the cell ability to migrate into the scratch showed that 
Aila inhibited migration of both cell lines (Fig. 8 A,B) in a dose-dependent way. However, the 
effect in CDDP-resistant cells was higher than in sensitive cells. Then, cell motility was assessed 
using a Boyden chamber assay assessing directional migration and invasion of cells. Results 
showed that Aila inhibited 253J B-V and 253J B-V C-r cell invasion in a concentration dependent 
way in both cell lines, but, interestingly, the invasion of the CDDP-resistant cells was affected at 
higher levels than the sensitive cells (Fig.  9). -
-V C-r. Data are shown as percentages of inhibition versus the control 
invasion measured on untreated cells. In both migration assays, doses and timing of treatments 
minimized the possible confounding effects due to the Aila effect on cell growth. 
 
Discussion 
In the present study, Aila was found to be able to inhibit the proliferation of sensitive and CDDP 
resistant bladder cancer cells with the same effectiveness. The inhibition of proliferation mostly 
depended on the accumulation of cells in G0/G1 cell cycle phase of cell cycle, which, in turn, could 
be dependent on the Nrf2, Yap and c-Myc down-regulation. Nrf2 and YAP expression are increased 
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in resistant cells (Ciamporcero et al, 2016; Ciamporcero et al., 2018) and both play an important 
role in reducing proliferative capacity of cells. Beside the canonical Nrf2 role in orchestrating 
antioxidant response, accumulating evidence has established that  Nrf2 sustained proliferative 
signaling and that its reduction correlated with a reduction of cell proliferation (Rojo de la Vega et 
al., 2018). As a consequence, the down regulation of Nrf2 expression by Aila, could reduce the 
cytoprotective role of Nrf2, thus facilitating its own antiproliferative action. Another naturally 
occurring quassonoid, brusatol, extracted from the aerial parts of the Brucea javanica plant, has 
been shown to inhibit Nrf2 and to sensitize cancer cells to several chemotherapeutic drugs (Ren  et 
al., 2011). However, the brusatol-mediated inhibition of Nrf2 was transient,  persisting only 8 hours 
from the treatment   (Olayanju A et al., 2015).   On the contrary, we demonstrated that after 48 
hours the reduction of Nrf2 expression by Aila was still present, as well as the reduction of  the 
Nrf2 target  gene GSTA4.  The high antiproliferative effect of Aila in CDDP-resistant cells could be 
sustained not only by this persistent inhibition of Nrf2 expression, but also by the contemporary 
inhibition of YAP and Myc expression. Indeed YAP, through the activation of TEAD transcription 
factors, has been demonstrated to be implicated in the control of growth, oncogenic transformation, 
and epithelial-mesenchymal transition (Zao et al, 2008). Moreover, the binding of YAP with 
TEADs upregulates the expression of several growth promoting factors, among those is the well 
known oncogene c-myc (Neto- Silva et al., 2010). C-Myc and YAP-TEAD integrate mitogenic and 
mechanical cues at the transcriptional level to control cell proliferation and cell cycle entry (Croci  
et al., 2017).  
Traditionally, the cytotoxic effect of platinum compounds depend on the formation of intrastrand 
DNA cross-links [mostly double-strand breaks (DSB)], that lead to G2 arrest, apoptosis induction 
and generation of  oxidative stress (Yu et al., 2018). In this study we demonstrated that Aila 
affected cell growth through mechanisms other than cisplatin. In our cell models, Aila induced a 
cell cycle arrest in G0/G1 cells which can be in relation with the inhibition of YAP and c-Myc  
expression. Moreover, no evidence of  apoptosis induction was present, even after the treatment 
with the highest Aila concentration. Thus, apoptosis seems not be involved in the reduction of cell 
growth.  
Another important effect displayed by low doses of Aila regarded the inhibition of both random and 
directional migration. In determining this inhibitory effect, different pathways can be involved, in 
which both Nrf2 and  YAP play an important role (Zhang et al., 2016; Warren et al., 2018). 
In cancer cell lines, Nrf2 promoted the epithelial mesenchimal transition by down-regulation of E-
caderin, and Nrf2 knock-down greatly impaired migration and invasion  (Rojo de la Vega et  al., 
2018). For its part, YAP also is involved in cell invasion, since it induced epithelial mesenchimal 
transition in cancer cells and YAP knock-down rescued the expression of epithelial markers  (Zhao 
et al., 2008). 
 
Conclusions  
Our results demonstrated, for the first time, that Aila inhibited proliferation and migration of 
bladder cancer cells, by reducing Nrf2, YAP and c-Myc expression. Importantly, this effect was 
displayed in CDDP-resistant cancer cells in which the down-regulation of Nrf2 and YAP 
expressions was required to overcome the resistance. Since CDDP resistance is a common feature 
in muscle invasive urothelial carcinoma of the bladder after platinum-based chemotherapy (Shah et 
al., 2011), the identification  of a novel agent able to overcome this resistant disease is of great 
interest. From this point of view, Aila demonstrated  favourable drug-like properties due to its good 
bioavailability, high solubility and low hepatoxicity (He et al, 2015).  
In conclusion our results suggest that Aila may represent an important tool in the therapy of CDDP-
resistant bladder cancer and pave the way for further investigation in this field. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Acknowledgments: This work was supported by the Univers ex 
 Department of Clinical and Biological Sciences (BARG-RILO-16-01 and PIZS-RILO- 17-
01),   Department of  Sciences and Pharmaceutical Technology (DIAC-
RILO-16-01 and DIAC-RILO-17-01),  and CRT 2016 (TROFCRT1602). 
Conflict of interest 
The authors declare no conflict of interest. 
 
References 
Bray, D.H., Boardman, P., O'Neill, M.J., Chan, K.L., Phillipson, J.D., Warhurst, D.C., Suffness, M., 
1987. Plants as a source of antimalarial drugs 5. Activities of Ailanthus altissima stem constituents 
and of some related quassinoids. Phytother. Res. 1, 22 24.  
 
Chen, Y., Zhu, L., Yang, X., Wei, C., Chen, C., He, Y., Ji, Z., 2017. Ailanthone induces G2/M cell 
cycle arrest and apoptosis of SGC-7901 human gastric cancer cells. Mol Med Rep. 16, 6821-6827.  
 
Ciamporcero, E., Shen , H., Ramakrishnan, S., Yu Ku, S., Chintala, S., Shen, L., Adelaiye, R., 
Miles, K.M., Ullio, C., Pizzimenti, S., Daga, M., Azabdaftari, G., Attwood, K., Johnson, C., Zhang, 
J., Barrera, G., Pili, R., 2016. YAP activation protects urothelial cell carcinoma from treatment-
induced DNA damage. Oncogene. 35, 1541-1553.  
 
Ciamporcero, E., Daga, M., Pizzimenti, S., Roetto, A., Dianzani, C., Compagnone, A., Palmieri ,A., 
Ullio, C., Cangemi, L., Pili, R., Barrera, G., 2018. Crosstalk between Nrf2 and YAP contributes to 
maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radic Biol Med. 
115, 447-457.  
 
Croci, O., De Fazio, S., Biagioni, F., Donato, E., Caganova, M., Curti, L., Doni, M., Sberna, S., 
Aldeghi, D., Biancotto, C., Verrecchia, A., Olivero, D., Amati, B., Campaner, S., 2017. 
Transcriptional integration of mitogenic and mechanical signals by Myc and YAP. Genes Dev.  31, 
2017-2022.  
 
Dianzani, C., Minelli, R., Gigliotti, C.L., Occhipinti, S., Giovarelli, M., Conti, L., Boggio, E., 
Shivakumar, Y., Baldanzi, G., Malacarne, V., Orilieri, E., Cappellano, G., Fantozzi, R., Sblattero, 
D., Yagi, J., Rojo, J.M., Chiocchetti, A., Dianzani, U., 2014. B7h triggering inhibits the migration 
of tumor cell lines. J Immunol. 192, 4921-4931.  
 
Harvey, K.F., Zhang, X., Thomas, D.M., 2013. The Hippo pathway and human cancer. Nat Rev 
Cancer  13, 246 257.  
 
Hayden, A., Douglas, J., Sommerlad, M., Andrews, L., Gould, K., Hussain, S., Thomas, G.J., 
Packham, G., Crabb, S.J., 2014. The Nrf2 transcription factor contributes to resistance to cisplatin 
in bladder cancer. Urol Oncol. 32, 806-814.  
 
He, Y., Peng, S., Wang, J., Chen, H., Cong, X., Chen, A., Hu, M., Qin, M., Wu, H., Gao, S., Wang, 
L., Wang, X., Yi, Z., Liu, M., 2016. Ailanthone targets p23 to overcome MDV3100 resistance in 
castration-resistant prostate cancer. Nat Commun. 7, 13122.  http://doi.org/10.1038/ncomms13122 
 
Itoh, K.,Tong, KI., Yamamoto, M., 2004. Molecular mechanism activating Nrf2-Keap1 pathway in 
regulation of adaptive response to electrophiles. Free Radic Biol Med.  36, 1208 1213. 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Kim, H.M., Kim, S.J., Kim, H.Y., Ryu, B., Kwak, H., Hur, J., Choi, J.H., Jang, D.S., 2015. 
Constituents of the stem barks of Ailanthus altissima and their potential to inhibit LPS-induced 
nitric oxide production. Pharm Biol. 54, 1641 1648.  
 
Liu, J.Y., Li, Y.H., Lin, H.X., Liao, Y.J., Mai, S.J., Liu, Z.W., Zhang,  Z.L., Jiang,  L.J., Zhang, 
J.X., Kung, H.F.,  Zeng, Y.X.,  Zhou, F.J.,  Xie, D., 2013. Overexpression of YAP 1 contributes to 
progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC 
Cancer. 13,349. http://doi.org/10.1186/1471-2407-13-349 
 
Madersbacher, S., Hochreiter ,W., Burkhard, F., Thalmann, G.N., Danuser, H., Markwalder, R., 
Studer, U.E., 2003. Radical cystectomy for bladder cancer today a homogeneous series without 
neoadjuvant therapy. J Clin Oncol. 21, 690 696. 
 
Neto-Silva, R.M., de Beco, S., Johnston, L.A., 2010. Evidence for a growth-stabilizing regulatory 
feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap. Dev Cell. 19, 507
520.  
 
Ni, Z., Yao, C., Zhu, X., Gong, C., Xu, Z., Wang, L., Li, S., Zou, C., Zhu, S., 2017. Ailanthone 
inhibits non-small cell lung cancer cell growth through repressing DNA replication via 
downregulating RPA1. Br J Cancer. 117, 1621-1630.  
 
No, J.H., Kim, Y.B., Song, Y.S., 2014. Targeting nrf2 signaling to combat chemoresistance. J 
Cancer Prev.19, 111-117.  
 
Olayanju, A., Copple, I.M., Bryan, H.K., Edge, G.T., Sison, R.L., Wong, M.W., Lai, Z.Q., Lin, 
Z.X., Dunn, K., Sanderson, C.M., Alghanem, A.F., Cross, M.J., Ellis, E.C., Ingelman-Sundberg, 
M., malik, H.Z., Kitteringham N.R., Goldring, C.E., Park, B.K., 2015. Brusatol provokes a rapid 
and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-
implications for therapeutic targeting of Nrf2. Free Radic Biol Med. 78,  202 212. 
 
Ren, D., Villeneuve, N.F., Jiang, T., Wu, T., Lau, A., Toppin, H.A., Zhang, D.D., 2011. Brusatol 
enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc 
Natl Acad Sci U S A. 108, 1433 1438. 
 
Rojo de la Vega, M., Chapman, E., Zhang, D.D., 2018.  NRF2 and the Hallmarks of Cancer. Cancer 
Cell. pii: S1535-6108(18)30127-2. https://doi.org/10.1016/j.ccell.2018.03.022
 
Schneider, C.A., Rasband, W.S., Eliceiri, K.W., 2012. NIH Image to ImageJ: 25 years of image 
analysis Nat. Methods  9, 671-675. 
 
Shah, J.B., McConkey, D.J., Dinney, C.P., 2011. New strategies in muscle-invasive bladder cancer: 
on the road to personalized medicine. Clin Cancer Res. 17, 2608 2612. 
 
Sylvester , P.W., 2011. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular 
growth and viability. Methods Mol. Biol., 716, 157-168. 
 
Tao, G., Kahr, P.C., Morikawa, Y., Zhang, M., Rahmani, M., Heallen, T.R., Li, L., Sun, Z., Olson, 
E.N., Amendt, B.A., Martin, J.F., 2016. Pitx2 promotes heart repair by activating the antioxidant 
response after cardiac injury. Nature. 534, 119-123.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Wang, R., Xu, Q., Liu, L., Liang, X., Cheng, L., Zhang, M., Shi, Q., 2016. Antitumour activity of 2-
dihydroailanthone from the bark of Ailanthus altissima against U251. Pharm Biol. 54, 1641 1648.  
 
Warren, J.S.A., Xiao, Y., Lamar, J.M., 2018. YAP/TAZ Activation as a Target for Treating 
Metastatic Cancer. Cancers (Basel). 10(4), pii: E115. http://doi.org/10.3390/cancers10040115 
 
Yu, W., Chen, Y., Dubrulle, J., Stossi, F., Putluri, V., Sreekumar, A., Putluri, N., Baluya, D., Lai, 
S.Y., Sandulache ,V.C., 2018. Cisplatin generates oxidative stress which is accompanied by rapid 
shifts in central carbon metabolism. Sci Rep. 8(1),4306. http://doi.org/10.1038/s41598-018-22640-y 
 
Zhang, C., Wang, H.J., Bao, Q.C., Wang, L., Guo, T.K., Chen, W.L., Xu, L.L., Zhou, H.S., Bian, 
J.L., Yang,YR., Sun, H.P., Xu, X.L., You, Q.D., 2016. NRF2 promotes breast cancer cell 
proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction. Oncotarget. 7, 
73593-73606.  
 
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J.D., Wang, C.Y., Chinnaiyan, A.M., Lai, 
Z.C., Guan, K.L.,  2008. TEAD mediates YAP-dependent gene induction and growth control. 
Genes Dev.  22, 1962 1971. 
  
Zhao, B., Li, L., Tumaneng,  K., Wang, C.Y., Guan,  K.L., 2010.  A coordinated phosphorylation 
by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev. 24, 72 85.  
 
Zhuo, Z., Hu, J., Yang, X., Chen, M., Lei, X., Deng, L., Yao, N., Peng, Q., Chen, Z., Ye, W., 
Zhang, D., 2015. Ailanthone Inhibits Huh7 Cancer Cell Growth via Cell Cycle Arrest and 
Apoptosis In Vitro and In Vivo. Sci Rep. 5,16185. http://doi.org/10.1038/srep16185 
 
 
Figure legends 
 
Figure 1.   MTT and colony forming assays in 253J B-V  and  253J BV C-r cells. Panel A: MTT 
assay. Results are expressed as percent of control values, obtained after 72 hours from the treatment 
with the indicated concentrations of Aila or CDDP. Results  
experiments. ** 1vs  sensitive cells. Panel B: Colony forming assay. Cells were treated with 
the indicated concentrations of Aila or CDDP and cultured for 10 days.   
 
Figure 2. MTT and colony forming assays in 253J and  253J C-r cells. Panel A: MTT assay. 
Results are expressed as percent of control values, obtained after 72 hours from the treatment with 
the indicated concentrations of Aila or CDDP. Results  
experiments. ** 1vs  sensitive cells. Panel B: Colony forming assay. Cells were treated with 
the indicated concentrations of Aila or CDDP and cultured for 10 days.   
 
Figure 3. MTT and colony forming assays in T24 cells. Panel A: MTT assay. Results are expressed 
as percent of control values, obtained after 72 hours from the treatment with the indicated 
concentrations of Aila or CDDP. Results  Panel B: 
Colony forming assay. Cells were treated with the indicated concentrations of Aila or CDDP and 
cultured for 10 days.   
 
Figure 4. Panel A: Western blot analysis of Nrf2, expression in 253J B-V , 253J BV C-r, 253J, 
253J C-r and T24 cells in untreated (0) or treated with Aila at the indicated concentrations and 
harvested after 24 or 48 hours. Equal protein loading was confirmed by exposure of the membranes 
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to the anti- -actin antibody. Quantification of protein products was performed by densitometric 
scanning. -
independent experiments. Panel B: Quantification of protein products was performed by 
-actin signal and are indicated as the 
-  untreated control cells (C). 
 
Figure 5. Panel A: Western blot analysis of GSTA4 expression in 253J B-V, 253 J B-V C-r , 253J, 
253J C-r and  T24, untreated (0) or treated with Aila at the indicated concentrations and harvested 
after  48h. Equal protein loading was confirmed by exposure of the membranes to the anti- -tubulin 
antibody. Panel B: Quantification of protein products was performed by densitometric scanning. 
Data were normalized using the -tubulin 
independent experiments. ** p- - . untreated control cells (C). 
 
Figure 6. Panel A: Cell-
(0.1 -V and 253 J B-V C-r , at 24 hours. The data 
were captured by using a BD Accuri Flow cytometer. Results were extracted and analysed by using 
FCS Express Plus. Representative images and the relative percentages are shown. Panel B:  Percent 
-
V and 253J B-V C-  
 
Figure 7. Panel A: Western blot analysis  of YAP and c-Myc expression in 253J B-V and 253J B-V 
C-r cells untreated (0) or treated with Aila at the indicated concentrations and harvested after 24h 
and 48 hours. Equal protein loading was confirmed by exposure of the membranes to the anti- -
actin antibody.  Panel B: Quantification of protein products was performed by densitometric 
scanning. Data were normalized using the -actin 
three independent experiments. ** p- vs. untreated control cells (C). 
 
Figure 8. Panel A: wound healing assay at 0 (T0) and at 24 hours in 253J B-V and 253J B-V C-r 
cells untreated (C) or treated with Aila at the indicated concentrations. Panel B: Quantification of 
wound healing. The endpoint of the assay was measured by calculating the reduction in the width of 
the wound after 24 hours and compared to T0 which is set at 100%. The data of each assay was 
done from 3 independent experiments and shown as the mean  SD. **p-  and 
vs. C. 
 
Figure 9.  Invasion assay at 24 hours in 253J B-V and 253J B-V C-r cells treated with Aila at the 
indicated concentrations. Data are expressed as percentages of inhibition of cell invasion versus the 
control invasion measured on untreated cells. The data of each assay was done from 5 independent 
 **p-  and vs. C. 
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